TEST:

RlapsRisk™ BC

RlapsRisk™ BC is a CE-marked AI diagnostic to help pathologists and oncologists assess the risk of relapse of early breast cancer patients. Accurately discriminate between low and high risk breast cancer patients (ER+/HER2) using digital pathology slides (HES) to determine the right treatment pathway. Suitable for adults with primary invasive breast cancer (ER+/HER2-). RlapsRisk BC achieves 78% sensitivity and 80% specificity for post-treatment time-dependent accuracy at 5 years, outperforming current clinical scores in practice.